Prevention of Infective Endocarditis

Authored by , Reviewed by Dr John Cox | Last edited | Meets Patient’s editorial guidelines

Added to Saved items
This page has been archived. It has not been updated since 22/09/2015. External links and references may no longer work.
This article is for Medical Professionals

Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find the Infective Endocarditis article more useful, or one of our other health articles.

Read COVID-19 guidance from NICE

Treatment of almost all medical conditions has been affected by the COVID-19 pandemic. NICE has issued rapid update guidelines in relation to many of these. This guidance is changing frequently. Please visit to see if there is temporary guidance issued by NICE in relation to the management of this condition, which may vary from the information given below.

Antibiotic prophylaxis aims to reduce the incidence of infective endocarditis (IE).[1] A major shift in advice has emerged, culminating in new National Institute for Health and Care Excellence (NICE) guidance.[2] This challenges the efficacy of previous recommendations and to some extent the rationale for antibiotic prophylaxis. Measures to prevent IE need to go beyond antibiotic prophylaxis and the risks of antibiotic prophylaxis need to be considered. The new recommendations may prompt patient concern. The recommendations should lead to safer, better preventative measures which are ultimately easier to follow. There may be some confusion until the recommendations are fully understood and accepted.

IE is a serious condition and often difficult to diagnose. This can be appreciated from the separate Infective Endocarditis article.

Antibiotic prophylaxis for IE has traditionally been thought to work at one of three steps in the pathogenic process:

  • Killing the pathogen in the bloodstream before it can adhere to the heart valve.
  • Preventing adherence of bacteria to the thrombus forming on the valve.
  • Eradicating organisms that do attach to the thrombus.

However, the level of evidence of antibiotic prophylaxis efficiency is low and the indications of its prescription have been restricted in recent international guidelines.[3, 4]

  • Guidelines for use of antibiotic prophylaxis of IE have been developed often with international consensus. It should be remembered that:
    • They are unproven by randomised controlled trials.[1]
    • Even when guidelines are followed appropriately, they may fail to prevent IE. The guidelines exist to guide and inform but may occasionally be modified to fit particular circumstances.
    • Recent guidelines by the British Society for Antimicrobial Chemotherapy and by the American Heart Association have challenged existing dogma by highlighting the prevalence of bacteraemia that arise from everyday activities such as toothbrushing, the lack of association between episodes of IE and prior interventional procedures, and the lack of efficacy of antibiotic prophylaxis regimens.[5]
  • The scope for prevention is limited:
    • Only 15-20% of cases of IE result from the bacteraemia produced by an invasive procedure.
    • Only half of patients developing IE after invasive procedures were identified beforehand as candidates for antibiotic prophylaxis.
    • This means that only 10% of all cases of IE can be prevented by prophylactic antibiotics.

Against this background, NICE guidelines have recently been produced.[2] They have prompted a major shift in clinical practice.

These recommendations are described as 'a paradigm shift from current accepted practice'.[2] The guidance acknowledges that patients with pre-existing cardiac lesions are at risk of developing IE. However, NICE concluded that clinical and cost-effectiveness evidence supported the recommendation that at-risk patients undergoing interventional procedures should no longer be given antibiotic prophylaxis against IE. Further, NICE considers that there is evidence to suggest that current antibiotic prophylaxis regimens might result in a net loss of life. It should be emphasised that antibiotic therapy is still thought necessary 'to treat active or potential infections'.[2]

NICE key recommendations
  • Patients should not be offered antibiotics to prevent IE for any of the following procedures:
    • Any dental procedure.
    • An obstetric or gynaecological procedure, or childbirth.
    • A procedure on the bladder or urinary tract.
    • A procedure on the oesophagus, stomach or intestines.
    • A procedure on the airways (including ear, nose and throat and bronchoscopy).
  • Healthcare professionals should regard people with the following cardiac conditions as being at risk of developing IE:
    • Acquired valvular heart disease with stenosis or regurgitation.
    • Valve replacement.
    • Structural congenital heart disease (including surgically corrected or palliated structural conditions but excluding isolated atrial septal defect (ASD), fully repaired ventricular septal defect or fully repaired patent ductus arteriosus, and closure devices that are judged to be endothelialised).
    • Previous IE.
    • Hypertrophic cardiomyopathy.
  • Healthcare professionals should offer people at risk of IE clear and consistent information about prevention, including:
    • The benefits and risks of antibiotic prophylaxis and an explanation of why antibiotic prophylaxis is no longer routinely recommended.
    • The importance of maintaining good oral health.
    • Symptoms that may indicate IE and when to seek expert advice.
    • The risks of undergoing invasive procedures (including non-medical procedures such as body piercing or tattooing).
  • People at risk of IE who are receiving antimicrobial therapy because they are undergoing a gastrointestinal or genitourinary procedure at a site where there is a suspected infection should be offered an antibiotic that covers organisms that cause IE.
  • Investigate and treat promptly any episodes of infection in people at risk of IE, to reduce the risk of endocarditis developing.

It is still useful to consider which patients are at greatest risk of IE. However, the evidence does not support in practice a recommendation for antibiotic prophylaxis on such an assessment. These factors may still be used to identify patients with active infection requiring treatment.

Previous guidelines were devised empirically. A number of important factors were considered including:

  • Identification of at-risk patients. Patients at high, moderate and low risk of IE can be identified:
    • Highest-risk patients include those with:
      • All types of prosthetic valve.
      • Previous IE.
      • Surgically produced systemic or pulmonary shunts.
      • Congenital cyanotic heart disease.
    • Moderate-risk patients are those with:
      • Congenital cardiac conditions (other than cyanotic) but excluding isolated ASDs and surgical repairs of ASD or patent ductus arteriosus over six months previously.
      • Bicuspid aortic valves.
      • Acquired valve disease including rheumatic heart disease, mitral stenosis and calcific aortic stenosis.
      • Hypertrophic cardiomyopathy.
      • Mitral valve prolapse with regurgitation and with or without thickened leaflets.
    • Low-risk patients include those with:
      • Mitral valve prolapse without significant regurgitation.
      • Implanted pacemakers, defibrillators and coronary stents.
      • Innocent murmurs (except elderly patients where this may represent an at-risk calcified leaflet).
  • Different procedures carry different risk and type of bacteraemia (and, in theory, subsequent IE):
    • High-risk/moderate-risk procedures include invasive respiratory tract manipulation (for example, tonsillectomy and rigid bronchoscopy), gastrointestinal surgery, biliary surgery and urological surgery (including prostate surgery, cystoscopy and even urethral dilatation).[1]
    • Low-risk procedures not requiring prophylaxis include:
      • Most gynaecological procedures ranging from hysterectomy to insertion and removal of intrauterine devices where there is no infection.
      • Vaginal deliveries and caesarean section.
      • Cardiac catheterisation and angioplasties.
      • Endoscopy with or without biopsy (note that endoscopic retrograde cholangiopancreatography (ERCP) with biliary obstruction, dilatation of oesophageal strictures and injection of varices are moderate-risk procedures).
  • The perceived level of risk determined the appropriate antibiotic or combination of antibiotics used (including the appropriate time and dose).

Prophylaxis for dental procedures

Detailed prophylactic antibiotic regimens were recommended in the past.[1] However, even for high-risk patients, prophylaxis for all dental procedures involving dento-gingival manipulation or endodontics is no longer routinely recommended. Streptococci are, in theory, the most likely organisms. However, it has recently been concluded that there is no evidence to support the use of antibiotics to prevent endocarditis in dental procedures.[1] There may be reluctance to give up prophylaxis, and definitive trials balancing risk and benefit are unlikely to be forthcoming. There may be concern in patients at high risk of endocarditis (previous endocarditis, cardiac valve replacements, surgical systemic or pulmonary shunts). Even the use of chlorhexidine mouthwashes is no longer recommended.

Endocarditis prophylaxis for non-dental procedures

This was considered the most important form of prophylaxis and a cautious approach was taken.[1] Enterococci, streptococci and staphylococci are the most prominent organisms. All patients at risk (high and medium) were recommended to have prophylaxis.[1] Different procedures were looked at to see what percentage of different procedures were associated with bacteraemia. Consideration was also given to anecdotal evidence about which procedures were associated with endocarditis.[1] This enabled possible high-risk procedures to be identified. Routine prophylaxis is now no longer recommended and antibiotics would only be given to treat active infection (of whatever type) whilst awaiting (or with) microbiological advice.

Good oral hygiene is very important and good dental care should be facilitated. Patients with a cardiac anomaly putting them at risk of endocarditis (high-risk and moderate-risk patients above) should be referred for dental assessment. Any interventions should be performed at least 14 days before cardiac surgery, in order to allow mucosal healing. If cardiac surgery is performed as an emergency before dental assessment can be made, the assessment should be made at the earliest opportunity after surgery. Elective dental procedures should be delayed for three months post-surgery.

General measures and health education have enormous potential to prevent IE - for example:

  • Education of patients to inform doctors and healthcare workers of any underlying diagnosis/IE risk.
  • Since gingivitis is the most common cause of spontaneous bacteraemia, meticulous oral hygiene is important. Similarly, attention to skin hygiene is important in prevention.
  • Many cases of hospital-acquired infection can be prevented by better asepsis during handling and insertion of vascular catheters and prompt removal if infected. Poor hospital hygiene has been blamed for the rise in meticillin-resistant Staphylococcus aureus (MRSA).
  • Needle-exchange programmes, education and addiction treatment for drug-abusers.

Are you protected against flu?

See if you are eligible for a free NHS flu jab today.

Check now

Further reading and references

  1. Guidelines for the prevention of endocarditis; Report of the Working Party of the British Society for Antimicrobial Chemotherapy J Antimicrob Chemother. 2006 Jun

  2. Prophylaxis against infective endocarditis: Antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures; NICE Clinical Guideline (March 2008 - last updated July 2016)

  3. Thuny F, Grisoli D, Cautela J, et al; Infective endocarditis: prevention, diagnosis, and management. Can J Cardiol. 2014 Sep30(9):1046-57. doi: 10.1016/j.cjca.2014.03.042. Epub 2014 Apr 3.

  4. Thanavaro KL, Nixon JV; Endocarditis 2014: an update. Heart Lung. 2014 Jul-Aug43(4):334-7. doi: 10.1016/j.hrtlng.2014.03.009. Epub 2014 Apr 26.

  5. Gould FK, Elliott TS, Foweraker J, et al; Guidelines for the prevention of endocarditis: report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother. 2006 Jun57(6):1035-42. Epub 2006 Apr 19.

  6. 2015 ESC Guidelines for the management of infective endocarditis; European Society of Cardiology (Aug 2015)